Dr Danuta Jeziorska (she/her)
@dm_jeziorska
Biotech executive, serial founder, inventor & functional genomics expert. All views my own.
ID: 2294812056
16-01-2014 18:03:18
1,1K Tweet
807 Takipçi
447 Takip Edilen
Biotech is driving the game-changers of tomorrow to bring curative treatments to patients. Digital & data-driven skills are crucial to achieve this. I'm proud that Nucleome Therapeutics is part of BioIndustry Association (BIA) #bigimpact to encourage people with digital skills to pursue careers in biotech.
Enjoyed taking part in the Life Science & Healthcare Showcase hosted by Oxford University Innovation alongside other great UK companies with their origins in #Oxford
I am personally delighted to welcome Dr. Russell Greig to Nucleome Therapeutics as Non-Executive Chair of our Board of Directors and look forward to working closely with him.
I am delighted to highlight that the #DarkGenome Symposium, co-hosted by Nucleome Therapeutics Enara Bio and ROME Therapeutics, is coming up soon in #London, bringing together academic and industry leaders to continue to catalyse the therapeutic application of dark genome research.
Glad to contribute to the article that celebrates Creative Destruction Lab (CDL)-Oxford programme, based in the Oxford Saïd Insights University of Oxford Well done CDL-Oxford to have reached the milestone of collectively creating a record £1.3bn in euqity value in just four years of its founding.
Very pleased to be interviewed by Karen Tkach Tuzman as part of Nucleome’s Emerging Company Profile in BioCentury. You can read the full article here: biocentury.com/article/648954…
Proud of Nucleome Therapeutics being shortlisted in the Biotech of the Year category at the European European Lifestars Awards!
Great start to the Dark Genome Symposium! Delighted for Nucleome Therapeutics to co-host the event and looking forward to hearing the great line up of prominent speakers from academia, industry and investment community discussing the advancements in the field of the Dark Genome.
Delighted to welcome Dr. Stephen Harrison to our team at Nucleome Therapeutics as our Chief Scientific Officer, bringing 30 years of drug discovery and development expertise as the Company continues to build a portfolio of first-in-class targets.
If you’re passionate about translating your #functionalgenomics, #generegulation, #3dgenome, #darkgenome #genomics and/or #genetics expertise into impact on patients’ lives & you’re eager to work with a dedicated & creative team of experts, Nucleome Therapeutics would like to hear from you
Glad to feature in the latest instalment of Scrip, Citeline Commercial series by Eleanor Malone to talk about the transformative technologies poised to shape 2024 and how groundbreaking revolutionary leap into the #darkgenome has the potential to reshape the landscape of #drugdiscovery.
I’m passionate about promoting inclusivity of diverse leadership styles &proud of the inclusive enviroment that Nucleome Therapeutics is fostering. We need to embrace feminine features in both women &men as pillars of strength; &reshape the narrative of what it means to be a leader. #iwd
📽️University of Oxford spinout Nucleome Therapeutics is developing precision medicine for patients with complex diseases. Hear from co-founder Dr Danuta Jeziorska (she/her) 👇 Medical Sciences MRC WIMM RDM Oxford Oxford Science Enterprises The Oxford Science Park #spinouts #innovation #research #medtech #startedinOxford